Advertisement

Topics

Latest "Novella Clinical Resourcing" News Stories

11:50 EST 15th November 2018 | BioPortfolio

Here are the most relevant search results for "Novella Clinical Resourcing" found in our extensive news archives from over 250 global news sources.

More Information about Novella Clinical Resourcing on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Novella Clinical Resourcing for you to read. Along with our medical data and news we also list Novella Clinical Resourcing Clinical Trials, which are updated daily. BioPortfolio also has a large database of Novella Clinical Resourcing Companies for you to search.

Showing "Novella Clinical Resourcing" News Articles 1–25 of 15,000+

Thursday 15th November 2018

Dynex Technologies Receives CFDA Approval to Supply AGILITY Automated ELISA Processing System to China

Company’s portfolio approval demonstrates dedication to clinical labs in the Asia-Pacific region Dynex® Technologies, Inc., announced today that it received Chinese Food and Drug Administration (CFDA) approval to market its DYNEX AGILITY® instrument and software for quantitative immunoassay measurements of analytes, including proteins and mi...


uniQure Announces Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 15, 2018 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced initial clinical data in patients treated in the Company’s Phase IIb dose-confirmation study of AMT-061, an investigational AAV5-based gene therapy c...

MD Anderson Study Uses ImpediMed L-Dex Bioimpedance Spectroscopy to Assess Correlation with Limb Volume, Lymphatic Function in Lymphedema, Recommends L-Dex

Study concludes L-Dex correlates most closely with all measures and is the recommended metric when using BIS Publication of a new study to assess the validity of L-Dex bioimpedance spectroscopy (BIS) measurements for evaluating the effectiveness of interventions to treat lymphedema concludes that the L-Dex correlates most closely with all measur...


Lessons learned from a multicentre clinical trial in Africa

Joint Implant Surgeons Join Major Clinical Study to Transform the Knee and Hip Replacement Experience with Apple Watch® and iPhone® Technology

Selected as the only orthopedic practice in Ohio to participate in the Zimmer Biomet mymobility Clinical Study COLUMBUS, Ohio (PRWEB) November 15, 2018 Joint Implant Surgeons (JIS), a world leader in outpatient joint replacements and the premier orthopedic institution in the Midwest, is one of only nine group practice centers in the nation to be selected to participate in the Zimmer Biomet mymobi...

Blueprint Medicines’ Avapritinib Demonstrates Positive Results in Clinical Trial in Patients with Advanced Gastrointestinal Stromal Tumors

CAMBRIDGE, Mass., Nov. 15, 2018 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced updated data for the registration-enabling NAVIGATOR clinical trial of avapritinib, a potent and highly selective KIT and PDGFRA inhibitor in development for patients ...

Therapix Biosciences Ltd TRPX Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryTherapix Biosciences Ltd Therapix, formerly Nasvax Ltd is a clinical stage biopharmaceutical company that focuses on the development of cannabinoid based pharmaceuticals for the treatment of central nervous system disorders. Therapix's major product candidates include THX110, for the treatment of tourette syndrome, obstructive sleep apnea and chronic pain; THX130, for the treatment of mild ...

Respected IT Tech-Development Veteran Cindy Edge Joins HealthTech Solutions as Director of Engineering

Emerging health IT start-up HealthTech Solutions has named Cindy Edge as Director of Engineering. With over 30 years of experience delivering technology solutions to growth markets in the commercial software development arena, Edge will bring her leadership and knowledge

Partnerships, Licensing, Investments and MA Deals and Trends for July 2018 in Pharmaceuticals [Report Updated: 30092018] Prices from USD $1000

Partnerships, Licensing, Investments and MA Deals and Trends for July 2018 in PharmaceuticalsSummaryGlobalData's "Partnerships, Licensing, Investments and MA Deals and Trends for July 2018 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions MAs and financings in the pharmaceuticals industry. The report provides detailed...

Partnerships, Licensing, Investments and MA Deals and Trends for August 2018 in Pharmaceuticals [Report Updated: 30092018] Prices from USD $1000

Partnerships, Licensing, Investments and MA Deals and Trends for August 2018 in PharmaceuticalsSummaryGlobalData's "Partnerships, Licensing, Investments and MA Deals and Trends for August 2018 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions MAs and financings in the pharmaceuticals industry. The report provides deta...

European Institute of Oncology Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 08112018] Prices from USD $250

SummaryEuropean Institute of Oncology IEO is a research institute that conducts clinical and scientific research on cancer prevention, early diagnosis and treatment of cancer. The institute offers medical care services for breast tumors, lung tumors, cervical tumors, endometrial tumors, thoracic tumors, ovarian tumors, prostate tumors, urological tumors, stomach tumors, bowel tumors, and others. I...

Quotient expands Reading facility tripling GMP capacity

Quotient Sciences expanded its formulation development and clinical trial manufacturing operations at its Reading, UK facility.

Syros Announces Dose Escalation Data from Phase 1 Trial of SY-1365 Demonstrating Proof-of-Mechanism at Tolerable Doses in Patients with Advanced Solid Tumors

Dose Selected for Ongoing Expansion Cohorts in Ovarian and Breast Cancers Supported by Tolerability Profile and Early Signs of Clinical Activity Data Highlighted in Oral Plenary Session at EORTC-NCI-AACR Meeting Management to Host Conference Call and Webcast at 4:00 PM ET Today Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the dev...

PharmaCyte Biotech Completes Report of FDA Required Study Assessing Safety of Placement of Its Pancreatic Cancer Product

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature

Failure Shouldn’t Be Such an Orphan

The drug industry has  a huge stockpile of results on projects that have not worked. That much is clear – clinical success rates continue at about 10%, on average, so we have a steady stream failures of all kinds, for all reasons. It would be foolish not to learn as much as we could from

ESO Joins Forces with the Center for Patient Safety to Raise Awareness of Patient Safety in Clinical Encounters

Partnership works to create framework for EMS agencies to identify and prevent medical mistakes and patient harm ESO, the leading data and software company serving emergency medical services (EMS), fire departments and hospitals, and the

Nebula Genomics Launches Platform Offering Opportunity for Free DNA Sequencing and Control Over Personal Genomic Data

Individuals Can Contribute to Medical Breakthroughs and Get Rewarded for Sharing Health and Genomic Data While Maintaining Control Nebula Genomics today announced a first in direct-to-consumer genomics: the opportunity to have one’s whole genome sequenced, for free, through its new platform, nebula.org. The Nebula platform will connect consu...

Axonics® Granted Seven U.S. Utility Patents Related to its Implantable Sacral Neuromodulation Technology

Axonics Modulation Technologies, Inc., (NASDAQ: AXNX) developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and bowel dysfunction, announced

Litmus Health Wins Contract from the National Institutes of Health to Enhance Drug Development with Real World Data

Contract secured as industry accelerates adoption of wearables in clinical trials; company also releases first Device Census Report™ NEW YORK (PRWEB) November 15, 2018 Litmus Health, the research-ready infrastructure platform for real world data, today announced that the company has been awarded a $225,000 Phase I Small Business Innovation Research (SBIR) contract from the National Cancer Insti...

uBiome Awards Grant to Team of Urology Researchers at UCLA to Investigate Dietary Intervention in Prostate Cancer

The leader in microbial genomics awards grant to a team of researchers at the University of California Los Angeles to study effects on the microbiome due to fish oil consumption in men with prostate cancer. SAN FRANCISCO (PRWEB) November 15, 2018 Through its Microbiome Grant Initiative, uBiome, the leader in microbial genomics, has awarded microbiome research support in study design, planning, sa...

Minerva Neurosciences, Inc: Minerva Neurosciences to Host Roluperidone Update and Key Opinion Leader Discussion of Negative Symptoms in CNS/Psychiatric Diseases on November 20, 2018

Minerva management to provide update on Phase 3 clinical trial with roluperidone and single-dose escalation study findings Additional topics to include review of recent BDNF data with roluperidone ...

Hengrui Pharma Partners with Medidata to Accelerate Global Drug Research

Leading Sponsor in China to Deliver Innovative Therapies to Patients Worldwide with Medidata Cloud News summary: Hengrui adds Medidata Rave EDC, RTSM, Coder, Safety Gateway and Edge CTMS to support emerging market strategy Medidata Cloud enables unified data management for global clinical trial expansion...

$SLNO Announced clinical data from a Phase II investigating the effects of DCCR treatment on hyperphagia and fat loss in patients with Prader-Willi Syndrome https://globenewswire.com/news-release/2018/11/15/1652241/0/en/Soleno-Therapeutics-Presents-Clinic

$SLNO Announced clinical data from a Phase II investigating the effects of DCCR treatment on hyperphagia and fat loss in patients with Prader-Willi Syndrome https://globenewswire.com/news-release/2018/11/15/1652241/0/en/Soleno-Therapeutics-Presents-Clinical-Fat-Loss-Data-on-DCCR-at-the-Obesity-Society-Meeting-2018.html …

Heat Biologics, Inc.: Heat Biologics Reports Third Quarter 2018 Results and Provides Corporate Update

On track to report key clinical milestones beginning in Q4 2018 DURHAM, NC / ACCESSWIRE / November 15, 2018 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing therapies d...

Phivida Announces Q4 2018 Corporate Business Update

Phivida Holdings Inc (CSE:VIDA, OTCQX:PHVAF) ("Phivida"), which offers premium beverages and clinical products infused with active hemp extract, today announced its Q4 2018 corporate business update on milestones achieved and strategic initiatives underway. The post Phivida Announces Q4 2018 Corporate Business Update appeared first on Investing News Network.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks